Medifocus to present on Microfocus APA-1000 at Annual National Interdisciplinary Breast Center Conference

Mar 5 2011

Medifocus Inc. (OTC:MDFZF.PK and TSXV:MFS) is pleased to announce that two (2) clinical presentations of the Company's breast cancer treatment system, the Microfocus APA-1000, will be made at the 21^st Annual National Interdisciplinary Breast Center Conference , March 12-16, 2011 in Las Vegas , NV.

“Focused Microwave Thermotherapy in Combination with Neoadjuvant Anthracycline-Based Chemotherapy for Investigating Tumor Response of Large Invasive Breast Carcinomas: Phase III Clinical Trial Status.”

The first poster," Wide-Field Focused Microwave Thermotherapy for Invasive Breast Carcinomas: Positive Results for Small Randomized Clinical Studies for Early-Stage and Large Breast Tumors" summarizes the positive clinical data on large breast tumors, that when the Medifocus focused heat treatment was added to Standard of Care (SoC) chemotherapy, the median tumor shrinkage in the thermo-chemotherapy arm was 88.4% while for chemotherapy alone, the median tumor shrinkage was only 58.8%. This increase in median tumor shrinkage was statistically significant with a P value equal to 0.048. In addition, the poster summarizes the positive clinical data on early stage breast tumors, which showed that patients receiving the focused microwave thermotherapy treatment prior to surgery had 0% positive tumor margins compared to 9.8% positive tumor margins for patient receiving surgery alone. Reducing the risk of positive tumor margins is important in potentially reducing the recurrence of breast cancer.

The second poster, " Focused Microwave Thermotherapy in Combination with Neoadjuvant Anthracycline-Based Chemotherapy for Investigating Tumor Response of Large Invasive Breast Carcinomas: Phase III Clinical Trial Status." Outlines the pivotal Phase III clinical trial, designed to assess the safety and improvement in efficacy, as measured by increased tumor shrinkage, using the Company's focused microwave heat energy in combination with neo-adjuvant (pre-operative) chemotherapy over chemotherapy alone on large breast cancer tumors. A total of 238 patients will be entered into the pivotal study at six medical institutions in the USA and Canada as approved by the both the US Food and Drug Administration (FDA) and Health Canada.